Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.74, $0.14 better than the analyst estimate of $0.60. Revenue for the quarter came in at $221 million versus the consensus estimate of $199.95 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 EPS of $2.65-$2.75, versus the consensus of $2.61. Halozyme Therapeutics sees FY2023 revenue of $825-845 million, versus the consensus of $823 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.